On September 25, 2023, The Economist Technology Quarterly published a special issue exploring a variety of advances and approaches in the field of aging research that are working to help us all live healthier and longer. AFAR-affiliated experts and projects are highlighted across several articles.
In the articles "Living to 120 is becoming an imaginable prospect” and “Eating fewer calories can ward off ageing,” the TAME (Targeting Aging with MEtformin) Trial is highlighted among interventions poised to help extend healthspan and delay age-related diseases. (AFAR is helping raise funds for TAME.) AFAR Scientific Director and grantee Nir Barzilai, MD, discusses metformin's potential in a an accompanying video here.
In the article “Ageing bodies need to get rid of decrepit cells,” AFAR President and grantee James L. Kirkland, MD, shares his insights on senescent cells, the state of senescence research today, and the future potential of senolytic therapies to extend healthspan and lifespan.
In the article “Alternatives to the laboratory mouse,” AFAR Senior Scientific Director Steve Austad, PhD, shares his insights on the drawbacks of laboratory mice in longevity research, as well as the potential of alternative animal models such as red sea urchins and house sparrows.
Research on sirtuins and resveratrol by AFAR Board Member and grantee David Sinclair, PhD, AO, is also explored.
The articles are available with trial- and full-subscriptions to The Economist.
